Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06444438 |
Other study ID # |
2024-0224 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
May 1, 2024 |
Est. completion date |
May 30, 2025 |
Study information
Verified date |
March 2024 |
Source |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Subarachnoid hemorrhage (SAH) is a common and extremely critical disease in neurosurgery. The
mortality rate within 30 days of the onset of SAH is as high as 50%, and about 15% of SAH
patients die without reaching the hospital. Nearly half of the survivors have severe
neurological dysfunction, causing a huge burden to the families and society of the patients.
Recently, the introduction of the "glymphatic-meningeal lymphatic vessels" drainage system
has updated the current concept of intracranial cerebrospinal fluid circulation. After
subarachnoid hemorrhage, a large number of blood components flooded into the subarachnoid
space and entered the cerebrospinal fluid circulation, which directly affected the function
of the lymphatic-meningeal lymphatic drainage system. Many preclinical animal studies have
pointed out that the damage of the lymphatic-meningeal lymphatic drainage system is involved
in the aggravation of cerebral edema, neuroinflammation and hydrocephalus after SAH, which
ultimately leads to poor prognosis of patients.
However, at present, the changes of the glymphatic-meningeal lymphatic drainage system after
SAH have only been confirmed in animal models, and clinical evidence is lacking. With the
development of imaging technology, many research teams have confirmed the functional changes
of the lymphatic-meningeal lymphatic drainage system in Alzheimer's disease and Parkinson's
disease by using different sequences of non-invasive MRI, such as 3D T2-FLAIR, DTI-ALPS and
other sequences.
Description:
Subarachnoid hemorrhage (SAH) is a common and extremely critical disease in neurosurgery. The
mortality rate within 30 days of the onset of SAH is as high as 50% and about 15% of SAH
patients die without reaching the hospital. Nearly half of the survivors have severe
neurological dysfunction, causing a huge burden to the families and society of the patients.
Recently, the introduction of the "glymphatic-meningeal lymphatic vessels" drainage system
has updated the current concept of intracranial cerebrospinal fluid circulation. After
subarachnoid hemorrhage, a large number of blood components flooded into the subarachnoid
space and entered the cerebrospinal fluid circulation, which directly affected the function
of the lymphatic-meningeal lymphatic drainage system. Many preclinical animal studies have
pointed out that the damage of the lymphatic-meningeal lymphatic drainage system is involved
in the aggravation of cerebral edema, neuroinflammation, and hydrocephalus after SAH, which
ultimately leads to poor prognosis of patients.
However, at present, the changes in the glymphatic-meningeal lymphatic drainage system after
SAH have only been confirmed in animal models, and clinical evidence is lacking. With the
development of imaging technology, many research teams have confirmed the functional changes
of the lymphatic-meningeal lymphatic drainage system in Alzheimer's disease and Parkinson's
disease by using different sequences of non-invasive MRI, such as 3D T2-FLAIR, DTI-ALPS, and
other sequences.